Table 1. Correlation between clinico-pathological patient characteristics and the expression of insulin receptor in endothelial cells of tumor vessels (VIR) as well as tumor cells (EIR).
| Total | Vascular expression (VIR) | Epithelial expression (EIR) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | low (0/1+) n (%) | high (2+/3+) n (%) | negative n (%) | positive n (%) | ||||||||
| Gender | n p-Value(a) | 1580 | 1580 | 0.917 | 1580 | 0.092 | ||||||
| Male | 811 | (51.3) | 297 | (36.6) | 514 | (63.4) | 241 | (29.7) | 570 | (70.3) | ||
| Female | 769 | (48.7) | 279 | (36.3) | 490 | (63.7) | 199 | (25.9) | 570 | (74.1) | ||
| Age Group | n p-Value(a) | 1580 | 1580 | 0.374 | 1580 | 0.866 | ||||||
| < 71 years | 777 | (49.2) | 292 | (37.6) | 485 | (62.4) | 218 | (28.1) | 559 | (71.9) | ||
| ≥ 71 years | 803 | (50.8) | 284 | (35.4) | 519 | (64.6) | 222 | (27.6) | 581 | (72.4) | ||
| Localization | n p-Value(a) | 1499 | 1499 | 0.024 | 1499 | 0.556 | ||||||
| Left-sided | 910 | (60.71) | 313 | (34.4) | 597 | (65.6) | 259 | (28.5) | 651 | (71.5) | ||
| Right-sided | 589 | (39.29) | 237 | (40.2) | 352 | (59.8) | 159 | (27.0) | 430 | (73.0) | ||
| T-Category | n p-Value(b) | 1580 | 1580 | 0.093 | 1580 | 0.006 | ||||||
| T1 | 77 | (4.9) | 34 | (44.2) | 43 | (55.8) | 17 | (22.1) | 60 | (77.9) | ||
| T2 | 329 | (20.8) | 138 | (41.9) | 191 | (58.1) | 82 | (24.9) | 247 | (75.1) | ||
| T3 | 908 | (57.5) | 302 | (33.3) | 606 | (66.7) | 249 | (27.4) | 659 | (72.6) | ||
| T4a/b | 266 | (16.8) | 102 | (38.3) | 164 | (61.7) | 92 | (34.6) | 174 | (65.4) | ||
| T-Category (grouped) | n p-Value(a) | 1580 | 1580 | 0.005 | 1580 | 0.072 | ||||||
| T1/T2 | 406 | (25.7) | 172 | (42.4) | 234 | (57.6) | 99 | (24.4) | 307 | (75.6) | ||
| T3/T4a/T4b | 1174 | (74.3) | 404 | (34.4) | 770 | (65.6) | 341 | (29.0) | 833 | (71.0) | ||
| N-Category | n p-Value(b) | 1561 | 1561 | 0.843 | 1561 | < 0.001 | ||||||
| N0 | 866 | (55.5) | 314 | (36.3) | 552 | (63.7) | 203 | (23.4) | 663 | (76.6) | ||
| N1a/b/c | 334 | (21.4) | 115 | (34.4) | 219 | (65.6) | 101 | (30.2) | 233 | (69.8) | ||
| N2a/b | 361 | (23.1) | 136 | (37.7) | 225 | (62.3) | 129 | (35.7) | 232 | (64.3) | ||
| N-Category | n p-Value(a) | 1561 | 1561 | 0.958 | 1561 | < 0.001 | ||||||
| N0 | 866 | (55.5) | 314 | (36.3) | 552 | (63.7) | 203 | (23.4) | 663 | (76.6) | ||
| N+ (N1a/b/c, N2a/b) | 695 | (44.5) | 251 | (36.1) | 444 | (63.9) | 230 | (33.1) | 465 | (66.9) | ||
| M-Category | n p-Value(a) | 1580 | 1580 | 0.288 | 1568 | 0.028 | ||||||
| M1 | 182 | (11.5) | 73 | (40.1) | 109 | (59.9) | 63 | (34.8) | 118 | (65.2) | ||
| MX | 1398 | (88.5) | 503 | (36.0) | 895 | (64.0) | 373 | (26.9) | 1014 | (73.1) | ||
| UICC Stage | n p-Value(b) | 1580 | 1580 | 0.349 | 1580 | < 0.001 | ||||||
| I | 330 | (20.9) | 142 | (43.0) | 188 | (57.0) | 77 | (23.3) | 253 | (76.7) | ||
| IIA/B/C | 519 | (32.8) | 169 | (32.6) | 350 | (67.4) | 122 | (23.5) | 397 | (76.5) | ||
| IIIA/B/C | 550 | (34.8) | 193 | (35.1) | 357 | (64.9) | 179 | (32.5) | 371 | (67.5) | ||
| IVA/B | 181 | (11.5) | 72 | (39.8) | 109 | (60.2) | 62 | (34.3) | 119 | (65.7) | ||
| L-Category | n p-Value(a) | 1580 | 1580 | 0.306 | 1580 | 0.008 | ||||||
| L0 | 1184 | (74.9) | 423 | (35.7) | 761 | (64.3) | 309 | (26.1) | 875 | (73.9) | ||
| L1 | 396 | (25.1) | 153 | (38.6) | 243 | (61.4) | 131 | (33.1) | 265 | (66.9) | ||
| V-Category | n p-Value(a) | 1579 | 1579 | 0.312 | 1579 | 0.828 | ||||||
| V0 | 1466 | (92.8) | 540 | (36.8) | 926 | (63.2) | 409 | (27.9) | 1057 | (72.1) | ||
| V1 | 113 | (7.2) | 36 | (31.9) | 77 | (68.1) | 30 | (26.5) | 83 | (73.5) | ||
| Pn-Category | n p-Value(a) | 722 | 722 | 0.872 | 722 | 0.605 | ||||||
| Pn0 | 677 | (93.8) | 231 | (34.1) | 446 | (65.9) | 184 | (27.2) | 493 | (72.8) | ||
| Pn1 | 45 | (6.2) | 16 | (35.6) | 29 | (64.4) | 14 | (31.1) | 31 | (68.9) | ||
| Grading | n p-Value(a) | 1540 | 1540 | 0.837 | 1540 | 0.942 | ||||||
| Low grade (G1/G2) | 1254 | (81.4) | 442 | (35.2) | 812 | (64.8) | 347 | (27.7) | 907 | (72.3) | ||
| High grade (G3/G4) | 286 | (18.6) | 103 | (36.0) | 183 | (64.0) | 80 | (28.0) | 206 | (72.0) | ||
| R-Status | n p-Value(a) | 1535 | 1535 | 0.744 | 1535 | 0.053 | ||||||
| R0 | 1494 | (97.3) | 544 | (36.4) | 950 | (63.6) | 410 | (27.4) | 1084 | (72.6) | ||
| R1/R2 | 41 | (2.7) | 16 | (39.0) | 25 | (61.0) | 17 | (41.5) | 24 | (58.5) | ||
| Overall Survival [Months] | p-Value(c) | 1576 | 0.414 | 1576 | 0.007 | |||||||
| Total / Events / Censored | 1576/781/795 | 575/281/294 | 1001/500/501 | 437/244/193 | 1139/537/602 | |||||||
| Median Survival | 100.0 | 106.0 | 87.1 | 64.3 ± 10.0 | 127.2 | |||||||
| 95% C.I. | n.c. | n.c. | n.c. | 44.5 - 84.1 | n.c. | |||||||
| Survival after 5 years in % | 56.6 +/- 1.3 | n.c. | n.c. | 51.4 +/- 2.4 | 58.6 +/- 1.5 | |||||||
| Survival after 10 years in % | 47.5 +/- 1.4 | n.c. | n.c. | 40.8 +/- 2.6 | 50.1 +/- 1.6 | |||||||
| UICC II-Subgroup: Overall Survival | p-Value(c) | 519 | 0.043 | |||||||||
| Total / Events / Censored | 121/61/60 | 396/157/239 | ||||||||||
| Median Survival | 106.1 +/- 17 | n.c. | ||||||||||
| 95% C.I. | n.c. | n.c. | ||||||||||
| UICC stage II: survival after 5 years in % | 59.3 +/- 4.5 | 69.0 +/- 2.3 | ||||||||||
| UICC stage II: survival after 10 years in % | 44.7 +/- 5.1 | 57.0 +/- 2.7 | ||||||||||
| Tumor Specific Survival [Months] | p-Value(c) | 1559 | 0.205 | 1559 | 0.011 | |||||||
| Total / Events / Censored | 1559/526/1033 | 571/183/388 | 988/343/645 | 431/168/263 | 1128/358/770 | |||||||
| Median Survival | n.c. | n.c. | n.c. | n.c. | n.c. | |||||||
| 95% C.I. | n.c. | n.c. | n.c. | n.c. | n.c. | |||||||
| Survival after 5 years in % | 66.8 +/- 1.2 | n.c. | n.c. | 61.6 +/- 2.4 | 68.8 +/- 1.4 | |||||||
| Survival after 10 years in % | 62.7 +/- 1.4 | n.c. | n.c. | 56.7 +/- 2.7 | 65.0 +/- 1.6 | |||||||
| UICC II-Subgroup: Tumor Specific Survival | p-Value(c) | 519 | 0.045 | |||||||||
| Total / Events / Censored | 119/34/85 | 394/80/314 | ||||||||||
| Median Survival | n.c. | n.c. | ||||||||||
| 95% C.I. | n.c. | n.c. | ||||||||||
| UICC stage II: survival after 5 years in % | 73.1 +/- 4.2 | 81.8 +/- 2.0 | ||||||||||
| UICC stage II: survival after 10 years in % | 66.0 +/- 5.2 | 76.9 +/- 2.4 | ||||||||||
(a) Fisher‘s exact test
(b) Kendall‘s tau test
(c) Log-rank test
Abbreviations: n.c. = not calculated.